Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis

Hepatology Research

Volumn 39, Issue 5, 2009, Pages 432-438

  Kurokawa, Mika ^a   Hiramatsu, Naoki ^a   Oze, Tsugiko ^a   Mochizuki, Kiyoshi ^a   Yakushijin, Takayuki ^a   Kurashige, Nao ^a   Inoue, Yuko ^a   Igura, Takumi ^a   Imanaka, Kazuho ^b   Yamada, Akira ^c   Oshita, Masahide ^d   Hagiwara, Hideki ^e   Mita, Eiji ^f   Ito, Toshifumi ^g   Inui, Yoshiaki ^c   Hijioka, Taizo ^h   Yoshihara, Harumasa ⁱ   Inoue, Atsuo ^j   Imai, Yasuharu ^k   Kato, Michio ^f   Kiso, Shinichi ^a   Kanto, Tatsuya ^a   Takehara, Tetsuo ^a   Kasahara, Akinori ^a   Hayashi, Norio ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c Hyogo Prefectural Nishinomiya Hospital   (Japan)

^d OSAKA POLICE HOSPITAL   (Japan)

^e Higashiosaka City General Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION   (Japan)

^g Japan Labour Health and Welfare Organization   (Japan)

^h MINAMI OSAKA GENERAL HOSPITAL   (Japan)

ⁱ OSAKA ROSAI HOSPITAL   (Japan)

^j OSAKA GENERAL MEDICAL CENTER   (Japan)

^k Ikeda Municipal Hospital   (Japan)

more..

Author keywords

Chronic hepatitis C; Continuous normalization of ALT; Hepatocellular carcinoma; Interferon plus ribavirin combination therapy; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPIRATION BIOPSY; BLOOD SAMPLING; CANCER RISK; CARCINOGENESIS; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; ECHOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VIRUS LOAD;

EID: 65449140955     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00477.x     Document Type: Article

References (28)

1. Takayasu K, Arii S, Ikai I etal. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
2. Taura K, Ikai I, Hatano E, Fujii H, Uyama N, Shimahara Y. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: An analysis of 610 patients over 16years old. Ann Surg 2006; 244: 265-73.
3. Shimada K, Sano T, Sakamoto Y, Kosuge T. A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10years or longer after curative hepatectomy. Cancer 2005; 104: 1939-47.
4. Kiyosawa K, Tanaka E, Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. In: Reesink HW, ed. Current Studies in Hematology Blood Transfusion. Basel: Karger, 1998; 161-80.
5. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991; 14: 969-74.
6. Tong MJ, el-Farra NS, Reikes AR, Co, RL. Clinical outcome after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
7. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk of hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
8. Okanoue T, Itoh Y, Minami M etal. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1148 patients. J Hepatol 1999; 30: 653-9.
9. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993; 104: 877-83.
10. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501-6.
11. Hiramatsu N, Hayashi N, Kasahara A et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural Interferon alpha. J Hepatol 1995; 22: 135-42.
12. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis C. A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-9.
13. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998; 27: 1394-402.
14. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
15. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
16. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
17. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
18. The METAVIR Cooperative Group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20: 15-20.
19. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon alpha2b plus ribavirin for 48weeks or for 24weeks versus interferon alpha2b plus placebo for 48weeks for treatment of chronic infection with hepatitis C virus. Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
20. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
21. Makiyama A, Itoh Y, Kasahara A et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 1616-22.
22. Hung CH, Lee CM, Lu SN et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat 2006; 13: 409-14.
23. Namiki I, Asahina Y, Kurosaki M et al. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Intervirology 2005; 48: 59-63.
24. Yu ML, Lin SM, Chuang WL etal. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther 2006; 11: 985-94.
25. Ikeda M, Fujiyama S, Tanaka M et al. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 122-8.
26. Arase Y, Ikeda K, Suzuki F et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007; 79: 1485-90.
27. Suzuki K, Ohkoshi S, Yano M et al. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver Int 2003; 23: 143-7.
28. Sarrazin C, Rouzier R, Wagner F et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype I nonresponders. Gastroenterology 2007; 132: 1270-8.